Utility of Progression-Free Survival at 24 Months (PFS24) to Predict Subsequent Outcome for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Enrolled on Randomized Clinical Trials: Findings from a Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 5853 Patients

Matthew J Maurer ,Bertrand Coiffier,Michael Pfreundschuh,Norbert Schmitz,Raoul Herbrecht,Ulrich Jaeger,Jocelyne Flament,John F Seymour,Hervé Tilly,Thomas M Habermann,Marita Ziepert,Tommy Fu,Francesco Merli,David Cunningham,Qian Shi,Hervé Ghesquières ,Christopher R Flowers ,Daniel J Sargent ,Corinne Haı̈oun ,Fang‐Shu Ou

doi:10.1182/blood.v128.22.3027.3027

Utility of Progression-Free Survival at 24 Months (PFS24) to Predict Subsequent Outcome for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Enrolled on Randomized Clinical Trials: Findings from a Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 5853 Patients

Matthew J Maurer , Bertrand Coiffier + Show 18 more

Open Access

https://doi.org/10.1182/blood.v128.22.3027.3027

Copy DOI

Journal: Blood	Publication Date: Dec 2, 2016
Citations: 5

Affiliation: Hôpital Lyon Sud, Saarland University, Asklepios Klinik St. Georg, Hôpital d'Hautepierre, Emory University, Medical University of Vienna, Bristol-Myers Squibb (Switzerland), Peter MacCallum Cancer Centre, University of Rouen, Mayo Clinic, Leipzig University, Ospedale Santa Maria, Hôpitaux Universitaires Henri-Mondor, Assistance Publique – Hôpitaux de Paris, Royal Marsden Hospital

#Advisory Committees #Research Funding + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Utility of Progression-Free Survival at 24 Months (PFS24) to Predict Subsequent Outcome for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Enrolled on Randomized Clinical Trials: Findings from a Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 5853 Patients

Full Text